Cite
HARVARD Citation
Geissler, M. et al. (n.d.). PD-030Final results of the randomized phase II VOLFI trial (AIO- KRK0109): mFOLFOXIRI + Panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild-type metastatic colorectal cancer (mCRC). Annals of oncology. p. . [Online].